A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Key facts
- Who runs it
- Syros Pharmaceuticals
- Where
- Ann Arbor, Baltimore, Birmingham, Chicago, Dallas, Houston, New York, and Pittsburgh, United StatesSee the 8 sites
- Trial code
- Status
- Suspended
- Phase
- Phase 1
- People taking part
- 16 people enrolled
- Started
- 17 Sept 2021
- Ended
- Apr 2024
- Type of study
- Interventional, 5 groups
- Treatments tested
- SY-2101
- Arsenic Trioxide
- Record updated
- 23 January 2024
- Why it stopped
- Prioritization
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participants must have a diagnosis of APL characterized by the presence of the t(15;17) translocation or PML/RARA gene expression via reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), or cytogenetics. Participants with low-risk APL may be eligible for all parts of this study; participants with high-risk APL are only eligible for the single-dose modules if they have completed a treatment regimen that included ATO within 6 months prior to the Screening Visit
- Participants must have received ATO plus ATRA induction therapy and must have received or be eligible and planning to receive consolidation therapy with ATO plus ATRA in alignment with National Comprehensive Cancer Network (NCCN) guidelines for low-risk APL prior to their enrollment in the study; or participants must have completed a treatment regimen that included ATO within 6 months prior to the Screening Visit
- Participants must be able to tolerate full dose ATO per NCCN guidelines
- Participants must be in morphological complete remission (CR) at the end of induction
- Participants must have a serum or high-sensitivity urine pregnancy test (for females of childbearing potential) that is negative at the Screening Visit and immediately prior to initiation of study treatment (first dose of study drug)
Who cannot take part
- Participants with a known active or chronic hepatitis B or active hepatitis C virus (HCV) infection. Participants with a history of HCV infection who have completed curative therapy for HCV at least 12 weeks before the Screening Visit and have a documented undetectable viral load at the Screening Visit are eligible for enrollment
- Participants who have not adequately recovered from a major surgery within 4 weeks of starting study drug administration
- Participants who received any other investigational agents within 4 weeks of the Screening Visit or <5 half-lives since completion of previous investigational therapy have elapsed, whichever is shorter
- Participants currently receiving treatment for a non-APL malignancy (not including basal cell carcinoma, non-melanoma skin cancer, cervical carcinoma in situ, or localized prostate cancer treated with hormone therapy). Participants with history of other cancers should be free of disease for at least 2 years prior to the Screening Visit
- Participants with an active, life-threatening, or clinically-significant uncontrolled systemic infection requiring hospitalization
- Participants who have a hypersensitivity to arsenic
- Immunocompromised participants with increased risk of opportunistic infections, including known human immunodeficiency virus (HIV)-positive participants with cluster of differentiation 4 (CD4) counts ≤350 cells/millimeters (mm\^3) or history of opportunistic infection in the last 12 months
- Participants who have experienced the following Grade ≥3 non-hematologic toxicities associated with ATO administration: QT prolongation, hepatotoxicity, neurotoxicity, cardiac function abnormalities. Participants who experienced other severe and life-threatening clinically-significant ATO-related AEs that are considered, in the judgement of the investigator, to increase participant risk with continued ATO treatment are also excluded; Other inclusion/exclusion criteria may apply
- Participants who have demonstrated relapse and therefore are not eligible for further consolidation
Where in United States
- University of MichiganAnn Arbor, United States
- John Hopkins UniversityBaltimore, United States
- University of Alabama at BirminghamBirmingham, United States
- Northwestern Memorial HospitalChicago, United States
- University of Texas Southwestern Medical CenterDallas, United States
- The University of Texas MD Anderson Cancer CenterHouston, United States
- Weill Cornell Medical CollegeNew York, United States
- UPMC Hillman Cancer CenterPittsburgh, United States
About the trial
What the trial wants to find out
SY-2101 is being studied as a treatment for participants with a type of leukemia called acute promyelocytic leukemia (APL). SY-2101 is an oral formulation of a drug called arsenic trioxide (ATO). ATO is already used to treat APL in a formulation that is given as an intravenous (IV) infusion (through a needle in the arm). SY-2101 is a formulation of ATO that is taken orally (by mouth).
Read full original descriptionShow less
This trial will include participants with APL in remission, who are receiving standard of care (SOC) treatment with all-trans-retinoic acid (ATRA) and IV ATO, during the consolidation phase of chemotherapy or within the past 6 months. The participants in this trial will receive continued treatment with ATO and ATRA to help keep their cancer from coming back. There will be some weeks when participants receive IV ATO and others when they receive SY-2101 (ATO taken orally). Participants with high-risk APL may be eligible for part 1 or 4 of the study for the 6 months following completion of their standard of care ATRA and ATO treatment.
The 5 groups in the trial
- Single-Dose PK Module: Sequence 1Treatment being tested
Participants will receive IV ATO in a fasted state on Day 1, SY-2101 in a fed state on Day 8, and SY-210 in a fasted state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.
Treatment: SY-2101 and Arsenic Trioxide
- Single-Dose PK Module: Sequence 2Treatment being tested
Participants will receive IV ATO in a fasted state on Day 1, SY-2101 in a fasted state on Day 8, and SY-2101 in a fed state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.
Treatment: SY-2101 and Arsenic Trioxide
- Single-Dose PK Comparability ModuleTreatment being tested
Participants will receive two single-dose treatments of SY-2101, with separated from one another by approximately 1 week and separated from any preceding IV ATO dose by at least 72 hours.
Treatment: SY-2101
- Multiple-Dose IV ModuleTreatment being tested
Participants will receive IV ATO, once daily (QD), 5 days/week for 28 days as a part of at least one cycle (Weeks 1 through 4) of SOC treatment consolidation.
Treatment: Arsenic Trioxide
- Multiple-Dose Oral ModuleTreatment being tested
Participants will receive SY-2101, QD, 5 days/week for 28 days as a part of one cycle (Cycle 4; Weeks 1 through 4) of SOC treatment consolidation.
Treatment: SY-2101
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Publications
- Record updated
- 23 January 2024